Bronchodilator reversibility test for broncho-obstructive syndrome detection and differential diagnosis of bronchial asthma and chronic obstructive pulmonary disease

Authors

  • V. P. Melnyk Private Higher Educational Establishment “Kyiv Medical University”, Ukraine,
  • O. V. Panasiuk Private Higher Educational Establishment “Kyiv Medical University”, Ukraine,
  • H. V. Sadomova-Andrianova Private Higher Educational Establishment “Kyiv Medical University”, Ukraine,
  • M. S. Molchanova Private Higher Educational Establishment “Kyiv Medical University”, Ukraine,
  • V. V. Scoryk Private Higher Educational Establishment “Kyiv Medical University”, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2019.2.161387

Keywords:

bronchodilation test, bronchial asthma, chronic obstructive pulmonary disease, differential diagnosis.

Abstract

 

Purpose – to analyze the method of bronchodilator reversibility test (BRT) at different doses of salbutamol in patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD).

Materials and methods. We examined 80 patients with broncho-obstructive syndrome, including 50 patients with a mild persistent BA (Group I) and 30 patients with COPD of moderate (course B) severity (Group II). All patients underwent routine methods of investigation: general clinical, laboratory, pulmonary function test, radiography of the chest organs (if needed), and statistical methods were used.

Results. Two methods of BRT were performed that differed in the dose of salbutamol to examine the patients with BA and COPD. All 50 patients with BA were first examined for bronchodilator reversibility with 200 micrograms of salbutamol and then, usually in 2 weeks, with 400 micrograms of salbutamol. Reversibility was in all the patients with BA within 15 minutes after 200 micrograms of salbutamol inhalation, but in 30 patients (60 %) it was full (12 % and more than the previous, >200 ml), and in 20 patients it was partial (less than 12 % or 200 ml). Full reversibility was found in 46 out of the 50 patients (92 %) within 30 minutes and it was 12 % or more (>200 ml) in all the patients only within 45 minutes. When using a salbutamol dose of 400 mg in BRT, the following results were obtained: full reversibility was in 47 (94 %) patients within 15 minutes and in another 3 patients within 30 minutes, that is in all the patients with BA.

16 (53.3 %) patients with COPD were considered nonreversible following administration a dose of salbutamol 200 micrograms within 15 minutes and partial reversibility was in 14 (46.7 %) patients with COPD. Partial reversibility was found in 10 patients (33.3 %) after 30 minutes, and 6 patients (20.0 %) were nonreversible or reversibility was within 2–3 %; in 4 out of the 6 patients (93.24 % in total) partial reversibility was only after 45 minutes and the remaining two patients were nonreversible even after 60 minutes of the examination.

BRT revealed partial reversibility at a salbutamol dose of 400 micrograms in 26 (86.6 %) patients with COPD within 15 minutes, in another 3 (96.6 %) patients – within 30 minutes and after 45 minutes – in all patients; none of the patients showed full reversibility.

Conclusions. According to conducted study, salbutamol for BRT can be used at a dose of 200 and 400 mcg in patients with BA, but the time of repeated spirometry should be different: at 200 mcg – not earlier than 30 minutes, or preferably 45 minutes; and at 400 mcg – 15 minutes after or a maximum of 30 minutes. In patients with COPD, the use of salbutamol at a dose of 200 mcg is impractical, but a dose of 400 mcg should be used and repeated spirometry is needed not earlier than 30 minutes after a test dose of the drug.

 

References

Boiko, D. M. (2016). Podviina bronkhodylatatsiina terapiia v pokrashhenni funktsii lehen u patsiientiv z KHOZL [Double bronchodilation therapy for improve lung function at patients with COPD]. Ukrainskyi pulmonolohichnyi zhurnal, 2, 51. [in Ukrainian].

Mostovoi, Yu. M., Demchuk, A. V., Konstantynovych, T. V., Sydorov, A. A., & Didenko, D. V. (2017). Pro zapalennia v «kvadratakh» KHOZL [COPD- about inflammation in «squares»]. Ukrainskyi pulmonolohichnyi zhurnall, 2, 58. [in Ukrainian].

Postma, D. S. & Rabe, K. F. (2015). The Asthma-COPD Overlap Syndrome. N Engl J Med, 373, 1241–1249. doi: 10.1056/NEJMra1411863.

(2013). Ukraina. MOZ. Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnomu obstruktyvnomu zakhvoriuvanni lehen: Nakaz MOZ Ukrainy vid 27 chervnia 2013 r. №555 [About approving and implementation of medical-technological documents with standardization of medical assistance with the case of chronic obstructive pulmonary disease Order of the Ministry of Health of Ukraine from June 27, 2013 r. №555]. [in Ukrainian].

Bilaj, I. M., Raznatovska, O. M. & Reznichenko, Yu. H. (2014). Klinichna farmakolohiia bronkholitykiv [Clinical pharmacology of bronchodilators]. Zaporizhzhia. [in Ukrainian].

Feshchenko, Yu. I., & Nazarenko, K. V. (2017). Stan mekhaniky dykhannia u khvorykh na bronkhoobstruktyvni zahvoriuvannia [Respiratory mechanics in patients with obstructive lung diseases]. Ukrainskyi pulmonolohichnyi zhurnal, 4, 17–22. [in Ukrainian].

Tolokh, O. S., Rudnytska, N. D., Chulovs'ka, U. B. & Vol'nytska, Kh. I. (2016). Kompensatsiia bronkhoobstruktyvnoho syndromu – vazhlyvyi aspekt kompleksnoi terapii bronkholehenevoi patolohii [Compensation of the broncho-obstructive syndrome - important aspect in complex therapy of bronchopulmonary disease]. Klinichna imunolohiia. Alerholohiia. Infektolohiia, 1, 26–32. [in Ukrainian].

Chabra, S. K. (2013). Test of reversibility of airway obstruction: Time for a review? Lung India, 30(1), 3–4. doi: 10.4103/0970-2113.106118

Downloads

How to Cite

1.
Melnyk VP, Panasiuk OV, Sadomova-Andrianova HV, Molchanova MS, Scoryk VV. Bronchodilator reversibility test for broncho-obstructive syndrome detection and differential diagnosis of bronchial asthma and chronic obstructive pulmonary disease. Zaporozhye Medical Journal [Internet]. 2019Apr.2 [cited 2024Nov.23];(2). Available from: http://zmj.zsmu.edu.ua/article/view/161387

Issue

No. 2 (2019)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)